SCHEMBL16181708

SCHEMBL16181708

CC1Nc2ccccc2S1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.57
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
CREBBP Q92793 2/20 0.46
BRD4 O60885 1/20 0.46
RAB9A P51151 2/20 0.40
TDP1 Q9NUW8 3/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 2/20 0.39
ALOX15 P16050 2/20 0.39
GAA P10253 2/20 0.39
CYP1A2 P05177 1/20 0.39
BCHE P06276 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
ALOX12 P18054 1/20 0.39
MAOA P21397 1/20 0.39
CNR1 P21554 1/20 0.39
ACHE P22303 1/20 0.39
PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12661831 1.00 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL338205 1.00 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL16711400 1.00 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL21808704 0.76 IDO1 (0.61) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL19621659 0.74 IDO1 (0.49) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL6185177 0.73 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL11502327 0.73 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL11118464 0.73 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL1754221 0.73 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4
SCHEMBL11539110 0.73 IDO1 (0.57) IDO1MEN1KMT2ACREBBPBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024144717-A2 NOVEL TRIAZINE-DERIVED COMPOUNDS AND THEIR ANTICANCER EFFECTS ISTANBUL MEDIPOL UNIVERSITESI (TR) 2024-07-04 WO disclosed
CN-114516848-B Preparation method of polycarbonate high-temperature degradation resistant agent and polycarbonate composition 万华化学集团股份有限公司 2024-02-02 CN disclosed
CN-117024372-A Synthesis method of benzothiazoline 温州大学新材料与产业技术研究院 2023-11-10 CN disclosed
EP-3668948-B1 POLYMERISABLE LIQUID CRYSTAL MATERIAL AND POLYMERISED LIQUID CRYSTAL FILM MERCK PATENT GMBH (DE) 2023-10-25 EP disclosed
US-20230130269-A1 LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL CURED LAYER, OPTICAL FILM, POLARIZING PLATE, AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2023-04-27 US disclosed
WO-2022262671-A1 MACRO HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2022-12-22 WO disclosed
US-11518745-B2 Heterocyclic compounds for the treatment of neurological and psychological disorders ALKERMES PHARMA IRELAND LIMITED (IE) 2022-12-06 US disclosed
EP-3998324-A1 WAVELENGTH CONVERSION FILM, WAVELENGTH CONVERSION FILM FORMING COMPOSITION, AND CLUSTER-CONTAINING QUANTUM DOT PRODUCTION METHOD TOKYO OHKA KOGYO CO., LTD. (JP) 2022-05-18 EP disclosed
EP-3919489-A1 AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The National Institutes of Pharmaceutical R&D Co., Ltd (CN) 2021-12-08 EP disclosed
CN-108885373-B Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element 日产化学工业株式会社 2021-12-03 CN disclosed
EP-2428586-A1 Dimeric and trimeric nucleic acid dyes, and associated systems and methods Biotium Inc. (US) 2012-03-14 EP disclosed
EP-1473334-B1 JET PRINTING INK AND METHOD OF INK JET PRINTING FUJIFILM CORP (JP) 2011-11-09 EP disclosed
US-20100001635-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-01-07 US disclosed
EP-2116533-A1 GLUCOKINASE ACTIVATOR Kyorin Pharmaceutical Co., Ltd. (JP) 2009-11-11 EP disclosed
EP-2108690-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2009-10-14 EP disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 WO disclosed
US-7459450-B2 Neuropeptide receptor modulators SCHERING CORPORATION (US) 2008-12-02 US disclosed
EP-1564259-B1 Azo dye, colored curable composition, color filter and producing method therefor FUJIFILM CORP (JP) 2008-03-12 EP disclosed
US-20070281937-A1 Ion Channel Modulators SCION PHARMACEUTICALS, INC. 2007-12-06 US disclosed
WO-2005097112-A2 ION CHANNEL MODULATORS WYETH (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281937-A1 Ion Channel Modulators CACNA1B, CACNA1C, TRPV1 IDO1 4094/4885MEN1 3147/4885KMT2A 3236/4885
US-20100001635-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, ILF2, L1CAM IDO1 1659/4885MEN1 3696/4885KMT2A 2435/4885
US-11518745-B2 Heterocyclic compounds for the treatment of neurological and psychological disorders GABBR1, GABBR2, GABRE IDO1 762/4885MEN1 1443/4885KMT2A 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.